Compare ResMed Inc. (RMD) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Vanguard Short Term Corporate Bond ETF — how do they compare? ResMed Inc. trades at $230.12 (market cap $31.89B), while Vanguard Short Term Corporate Bond ETF trades at $77.3 (market cap $51.90B). The key difference: Vanguard Short Term Corporate Bond ETF is the larger of the two by market cap, and ResMed Inc. pays a 1.16% dividend while Vanguard Short Term Corporate Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Vanguard Short Term Corporate Bond ETF for 52 Days on average.
| RMD | VCSH | |
|---|---|---|
Market Cap | $31.89B | $51.90B |
Volume | 618,314 | 2,892,221 |
Sector | Health | Fixed Income |
52-Week High | $277.88 | $80.20 |
52-Week Low | $182.82 | $77.03 |
Typical Hold Time | 51 Days | 52 Days |
Enterprise Value | $31.24B | — |
Dividend Yield | 1.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $230.91, up 2.18% today, with a bullish technical signal and strong fundamentals. The company reported consistent earnings beats in recent quarters, with Q3 2026 EPS expected at $2.68. Revenue grew to $5.15B in 2025, with a net income margin of 26.94%. Analyst consensus is a buy, with a $242.70 price target. Recent news highlights EPS growth targets of 12%-14% and participation in investor conferences.
Outlook is positive due to robust earnings growth and market share gains, but risks include competitive pressures and regulatory investigations. The stock offers upside to the consensus target, supported by institutional buying and solid cash flow generation.
VCSH trades at $77.285 with minimal daily movement (+0.02%), showing technical bearish signals from moving averages while oscillators remain neutral. The ETF maintains a competitive 4.5% dividend yield with a low 0.03% expense ratio, though recent analysis suggests credit spreads appear tight. Recent institutional activity shows mixed positioning with both stake increases and reductions reported.
The short-term corporate bond ETF faces headwinds from potential rate environment shifts while offering higher yields than treasury alternatives. Limited price appreciation potential exists given current technical positioning and market expectations of sustained rates, making it suitable for income-focused investors comfortable with corporate credit risk exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
